Home > Health > Increasing Incidence Rate of AIDS Is Driving the Kaposi Sarcoma Market

Increasing Incidence Rate of AIDS Is Driving the Kaposi Sarcoma Market

Added: (Fri Jan 12 2018)

Pressbox (Press Release) - Kaposi sarcoma (KS) can be categorized into epidemic (AIDS-related) KS, classic (Mediterranean) KS, endemic (African) KS, iatrogenic (transplant-related) KS and KS in HIV negative men who have sex with men. KS is the type of cancer which develop due to the cells that line lymph or blood vessels, abnormal cells of KS form purple, red, or brown blotches or tumors on the skin called as lesions. In US, with the AIDS epidemic, the rate of KS increased more than 20 times — peaking at about 47 cases per million people (per year) in the early 1990s.
Request for TOC @ https://www.goldsteinresearch.com/toc-request/global-kaposi-sarcoma-market-analysis-size-forecast-2016-2024
Patent expiries of several blockbuster drugs at the increasing pace, high rate of diagnosis of the condition, rising organ transplantation procedures, rising number of regional vendors, government initiatives, prevalence of HIV AIDS, tourism to the countries with KS cases, ease in availability of drugs and introduction of innovative and generic drug as well as therapies are bolstering underlying demand for Kaposi Sarcoma market. However, rising cost of treatment across developing and less developed economies, decline in supply of drugs due to wide demand-supply gap and less awareness among people is hampering the KS market.
Kaposi sarcoma market is making strides. According to Goldstein Research, global Kaposi sarcoma market has increased at a CAGR of 2.25% over the forecast period that will exhibit valuation of USD 0.15 billion by 2024 rising from USD 0.11 billion in 2016.
Among the treatments segment, antiretroviral therapy lead the global Kaposi sarcoma market due to the high incidence rate of AIDS-related Kaposi sarcoma and tends to grow at an encouraging pace in the forecast period as well. While chemotherapy is expected to exhibit growth at the most promising pace in near future.
Regionally, North America is the leading contributor of revenue to the global Kaposi sarcoma market owing to high rate of diagnosis of the condition and the easy availability of drugs. Middle East and Africa region is the promising market of Kaposi sarcoma attributable to increased prevalence of AIDS induced Kaposi sarcoma in Eastern Africa.
Global Kaposi Sarcoma market report also provides competitive outlook for the major players which includes profiling of companies such as Johnson & Johnson, Merck & Co., Inc., Bristol Myers Squibb, Hoffman-La Roche, Inc., Pfizer, Inc., GlaxoSmithKline plc, and Eli Lilly and Co, etc
Send us Sample Request @ https://www.goldsteinresearch.com/request-sample/global-kaposi-sarcoma-market-analysis-size-forecast-2016-2024
About Goldstein Research
Goldstein Research is a leading market research and consulting firm in US, currently has a strong presence in the American and Asian countries. In the next five years, we strive to expand our reach to 50+ nations spanning across Europe, Asia and parts of the Middle East and Africa. We strive to realize a strong brand presence globally through our quality research and forecasting solutions.
Our mission is simple: to develop insightful business solutions, help our clients make powerful future decisions to keep them well ahead of the game which is the market, and leave a mark across businesses and communities through our well-defined ideas and clearcut forecasts. Backed up by reliable research and impactful statistics, our business solutions empower our clients to grow at a fast pace despite unsettling fluctuations in the market. We believe in vigorous examination of the current market scenario and build around creative ideas and approaches that are most suitable to our clients’ needs and business agenda.
Contact for more Info:
Steve Blade
(Global Sales Head)
USA: + 1-646-568-7747
Canada: +1-437-886-1181
UK: +44-203-318-6627
sales@goldsteinresearch.com
www.goldsteinresearch.com

Submitted by:Steve Blade
Disclaimer: Pressbox disclaims any inaccuracies in the content contained in these releases. If you would like a release removed please send an email to remove@pressbox.co.uk together with the url of the release.